Abstract
The melanoma differentiation-associated gene-7 (mda-7) is a member of the interleukin-10 cytokine family and a novel tumor suppressor gene. Adenoviral-mediated mda-7 (Ad-mda7) gene transfer has tumor-specific growth inhibitory and proapoptotic effects in a broad spectrum of cancer cells. In breast cancer cells, adenoviral-induced mda-7 expression triggers antiproliferative effects by downregulation of survival signals, such as Bcl-2 and Akt. The anti-human epidermal growth factor receptor-2 (Her-2) monoclonal antibody, Trastuzumab (Herceptin), increases the sensitivity of Her-2/neu-overexpressing breast cancer cells to chemotherapeutic agents and radiotherapy. In this study, we evaluate the effects of treatment with Ad-mda7 and Herceptin combination therapy in a panel of Her-2/neu-overexpressing cell lines, and in established tumors in nude mice. Compared to individual treatments, the combination of Ad-mda7 and Herceptin elicits supra-additive antitumor activity in Her-2/neu-overexpressing tumor cell lines: increased cell death, cell cycle block and apoptosis. The Ad-mda7 and Herceptin interaction was shown to be synergistic by isobologram analysis. Ad-mda7 does not alter cell surface Her-2/neu levels, but the combination of Ad-mda7+Herceptin results in increased expression of cell surface E-cadherin with concomitant translocation of β-catenin from the nucleus to the cell membrane. In vivo, the combination of Ad-mda7 and Herceptin showed significantly increased antitumor activity (P<0.003) against Her-2/neu-overexpressing tumors. These data suggest that the combination of Ad-mda7 with Herceptin may be a novel therapy for breast cancer patients whose tumors overexpress Her-2/neu. The observed synergistic effect may improve treatment options for otherwise poorly responsive, Her-2-positive, breast cancer patients.
Similar content being viewed by others
References
Slamon DJ, Clark GM, Wong SJ, Levin WJ, Ullrich A, McGuire WL . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–182.
Yu D, Hung MC . Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000; 19: 6115–6121.
Baselga J, Norton L, Albaneli J, Young-Mee K, Mendelsohnm J . Recombinant humanized anti-Her2 antibody (Herceptin) enhances the anti-tumor activity of Paclitaxel and Doxorubicin against Her2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825–2831.
Winer EP, Burstein HJ . New combinations with Herceptin in metastatic breast cancer. Oncology 2001; 61 (Suppl 2): 50–57.
Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23: 2162–2171.
Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with Trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3656–3659.
Nieto Y, Vredenburgh JJ, Shpall EJ, Bearman SI, McSweeney PA, Chao N et al. Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. Clin Cancer Res 2004; 10: 7136–7143.
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639–2648.
Seidman AD, Fornier MN, Esteva FJ, Tan L, Captain S, Bach A et al. Weekly Trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19: 2587–2595.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER2/neu proto-oncogene in human breast cancer and ovarian cancer. Science 2001; 244: 707–712.
Tsai KB, Hou MF, Lin HJ, Chai CY, Liu CS, Huang TJ . Expression of HER-2/NEU oncoprotein in familial and non-familial breast cancer. Kaohsiung J Med Sci 2001; 17: 64–76.
Marty M, Cognetti D, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M et al. Efficacy and safety of Trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer given as first-line treatment: results of a randomized phase II trial by the M77001 Study Group. J Clin Oncol 2005; 23: 4265–4274.
Wolff AC, Bonetti M, Sparano JA, Wang M, Davidson NE, on behalf of ECOG. Cardiac safety of Trastuzumab in combination with pegylated liposomal doxorubicin and docetaxel in HER2-positive metastatic breast cancer: preliminary results of the Eastern Cooperative Oncology Group trial E3198. Proc Am Soc Clin Oncol 2003; 22: 18.
Trigo J, Climent MA, Gil M, Llunch A, Hornedo J, Gascon P et al. Cardiac safety and activity of a phase I study of 3-weely Myocet in combination with weekly Herceptin and paclitaxel in HER2-positive locally advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21: 61a (abtr 242).
Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB . Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995; 11: 2477–2486.
Jiang H, Su Z-Z, Lin JJ, Goldstein NI, Young CS, Fisher PB . The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci USA 1996; 93: 9160–9165.
Su Z-Z, Madireddi MT, Lin JJ, Young CS, Kitada S, Reed JC et al. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci USA 1998; 95: 14400–14405.
Mhashilkar AM, Schrock RD, Hindi M, Liao J, Sieger K, Kourouma F et al. Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. Mol Med 2001; 7: 271–282.
Su Z-Z, Madireddi MT, Lin JJ, Young CSH, Kitada S, Reed JC et al. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci USA 1998; 95: 14400–14405.
Saeki T, Mhashilkar A, Chada S, Branch C, Roth JA, Ramesh R . Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. Gene Therapy 2000; 7: 2051–2057.
Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst JA, Mumm JB, Leitner WW et al. MDA-7/IL-24 is a unique cytokine–tumor suppressor in the IL-10 family. Int Immunopharmacol 2004; 4: 649–667.
Saeki T, Mhashilkar A, Swanson X, Zumstein L, Branch C, Roth JA et al. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene 2002; 21: 4558–4566.
Madireddi MT, Su Z-Z, Young CS, Goldstein NI, Fisher PB . mda-7, a novel melanoma differentiation associated gene with promise for cancer gene therapy. Adv Exp Med Biol 2000; 465: 239–261.
Lebedeva IV, Su Z-Z, Chang Y, Kitada S, Reed JC, Fisher PB . The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene 2002; 21: 708–718.
Mhashilkar AM, Stewart AL, Sieger K, Yang HY, Khimani AH, Ito I et al. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. Mol Ther 2003; 8: 207–219.
Nishikawa T, Munshi A, Story MD, Ismail S, Stevens C, Chada S et al. Adenoviral-mediated mda-7 expression suppresses DNA repair capacity and radiosensitizes non-small-cell lung cancer cells. Oncogene 2004; 23: 7125–7131.
Pataer A, Vorburger SA, Barber GN, Chada S, Mhashilkar AM, Zou-Yang H et al. Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). Cancer Res 2002; 62: 2239–2243.
Pataer A, Chada S, Hunt KK, Roth JA, Swisher SG . Adenoviral melanoma differentiation-associated gene 7 induces apoptosis in lung cancer cells through mitochondrial permeability transition-independent cytochrome c release. J Thor Cardiovasc Surg 2003; 125: 1328–1335.
McKenzie T, Liu Y, Fannale M, Swisher SG, Chada S, Hunt KK . Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells. Surgery 2004; 136: 437–442.
Chada S, Mhashilkar AM, Ramesh R, Mumm JB, Sutton RB, Bocangel D et al. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther 2004; 10: 1085–1095.
Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K et al. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res 2003; 63: 5105–5113.
Chada S, Bocangel D, Ramesh R, Grimm EA, Mumm JB, Mhashilkar AM et al. mda-7/IL-24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Mol Ther 2005; 11: 724–733.
Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N et al. Intratumoral Injection of INGN241, a non-replicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL-24): biologic outcome in advanced cancer patients. Mol Ther 2005; 11: 160–172.
Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, Sahin AA, Read CM, Prieto VG et al. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer 2001; 94: 54–59.
Wheelock MJ, Johnson KR . Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol 2003; 19: 207–235.
Christofori G . Changing neighbors, changing behaviour: cell adhesion molecule-mediated signaling during tumor progression. EMBO J 2003; 22: 2318–2323.
Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, Lebedeva IV et al. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene 2001; 20: 7051–7063.
Christofori G, Semb H . The role of the cell adhesion molecule E-cadherin as a tumor suppressor gene. Trends Biochem Sci 1999; 24: 73–76.
Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G, Page DL . Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci USA 1991; 88: 10435–10439.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bocangel, D., Zheng, M., Mhashilkar, A. et al. Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells. Cancer Gene Ther 13, 958–968 (2006). https://doi.org/10.1038/sj.cgt.7700972
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700972
- Springer Nature America, Inc.
Keywords
This article is cited by
-
Combination of adenoviruses expressing melanoma differentiation-associated gene-7 and chemotherapeutic agents produces enhanced cytotoxicity on esophageal carcinoma
Cancer Gene Therapy (2014)
-
Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8+ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
Cancer Gene Therapy (2011)
-
Tumour suppressor function of MDA-7/IL-24 in human breast cancer
Cancer Cell International (2010)